Lidocaine-ACOS, 6 mg/dose 38 g
€1.00
Out of stock
(E-mail when Stock is available)
Pharmacotherapeutic group
Local anesthetic agent
ATX code: N01BB
Pharmacodynamics:
Lidocaine is an amide type local anesthetic.
The local anesthetic action is due to reversible inhibition of nerve conduction by blockade of sodium channels in the nerve endings, thus preventing generation of impulses at the end of sensitive nerves and conducting of pain impulses along the nerve fibers.
Lidocaine has a rapid onset of action, high anesthetic activity and low toxicity.
In local application it dilates blood vessels and has no local irritant effect. It has analgesic effect.
The effect shall develop 1-5 minutes after application to the mucous membranes or skin and shall last for 10-15 minutes.
Pharmacokinetics:
It is quickly absorbed from mucous membranes (especially pharynx and respiratory tract) the degree of absorption of the drug is determined by the degree of blood supply to the mucous membrane by the total dose of the drug, location of site and duration of application. After application to the mucous membrane of the upper respiratory tract it is partially swallowed and inactivated in the gastrointestinal tract.
The time of reaching maximum concentration (ÒCmax) in plasma when applied to the mucous membrane of the oral cavity and upper respiratory tract is 10-20 minutes. Protein binding depends on the drug concentration and is 60-80% at drug concentration of 1-4 µg/ml (43-172 µmol/L). Fast drug distribution (half-life (T1/2) of distribution phase is 6-9 min) goes first to well supplied with blood tissues (heart, lungs, brain, liver, spleen) and then to fat and muscle tissues. It penetrates through the blood-brain barrier and the placental barrier and is secreted with the mother’s milk (40% of the concentration in the mother’s plasma).
Metabolized in the liver (90-95%) with microsomal enzymes by dealkylation of the amino group and breaking the amide bond to form less active compared to lidocaine metabolites (monoethylglycincylidine and glycincylidine) with a T1/2 of 2 h and 10 h respectively. In liver disease the metabolic rate is reduced and is 50% to 10% of the normal value. It is excreted with the bile and the kidneys (up to 10% unchanged).
In chronic renal failure cumulation of metabolites is possible. Urinary acidification contributes to increased excretion of lidocaine.
Indications
The drug may be used for local anesthesia in the following cases:
in dentistry – for terminal (superficial) anesthesia: anesthetization of the injection area before local anesthesia; opening of superficial abscesses; before mucosal sutures; before fixation of crowns and bridges; in the treatment of gum inflammation periodontopathies; extirpation of milk teeth; removal of tartar;
in otolaryngology – operations on the septum and removal of nasal polyps; conducting electrocoagulation in the treatment of nosebleeds elimination of pharyngeal reflex and anesthesia of the injection needle site before removal of tonsils; opening of peritonsillar abscesses; puncture of maxillary sinus;
In obstetrics and gynecology – egshiziotomy and incision handling; removal of sutures; minor operations on the vagina and cervix; rupture of the hymen; treatment of thread abscesses;
In instrumental and endoscopic examinations – before insertion of a probe through the nose or mouth (including duodenal tube.
In radiographic examination – to eliminate nausea and pharyngeal reflex;
as an analgesic (analgesic) medication for burns (including sunburns); bites; contact dermatitis (including those caused by irritants).
Surface skin anesthesia for minor surgical interventions.
Active ingredient
Lidocaine
Composition
In 1 dose:
Active substance: lidocaine hydrochloride monohydrate (in terms of lidocaine hydrochloride) – 4.6 mg;
Auxiliary substances: 96% ethanol (rectified ethyl alcohol, grade “Extra”) – 18.4 mg, propylene glycol – 4.6 mg, sodium hydroxide (sodium hydroxide) – 0.23 mg, sodium saccharinate dihydrate (sodium saccharin) – 0.138 mg, racementol (menthol racemic) – 0.092 mg, purified water – up to 0.046 g.
How to take, the dosage
It is used topically and topically.
The dosage may vary depending on the indication and the size of the area to be anesthetized.
One dose of spray released by pressing the dispensing valve contains 46 mg of lidocaine.
Pressure recommendations for various applications:
Application area | Number of presses | |
Dentistry | 1-4 | |
Otorhinolaryngology | 1-4 | |
Endoscopic and instrumental examinations /td> | 2-3 | |
Obstetrics | 15-20 | |
Gynecology | 4-5 | |
Dermatology | 1-3 |
Weight | 0.065 kg |
---|---|
Shelf life | 3 years. Do not use after the expiration date printed on the package. |
Conditions of storage | In the dark place at a temperature not exceeding 25 ° C. Store out of the reach of children. |
Manufacturer | Sintez OAO, Russia |
Medication form | dosage for local and external use |
Brand | Sintez OAO |
Other forms…
Related products
Buy Lidocaine-ACOS, 6 mg/dose 38 g with delivery to USA, UK, Europe and over 120 other countries.